The Hair Loss Encyclopedia

Cepharanthine attenuates pulmonary fibrosis via modulating macrophage M2 polarization

September 2024 in “ BMC Pulmonary Medicine ”

Jiaqi Bao, Chang Liu, Huafeng Song, Zheying Mao, Wenxin Qu, Fei Yu, Yifei Shen, Jingjing Jiang, Xi Chen, Ruonan Wang, Qi Wang, Weizhen Chen, Shu‐Fa Zheng, Yu Chen

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

research Pharmacological Activity Of Cepharanthine

3 citations , June 2023 in “Molecules/Molecules online/Molecules annual”

Cepharanthine has many medicinal uses but needs improvement for better effectiveness.

research Bioavailability Enhancement of Cepharanthine via Pulmonary Administration in Rats and Its Therapeutic Potential for Pulmonary Fibrosis Associated with COVID-19 Infection

14 citations , April 2022 in “Molecules”

Pulmonary delivery of cepharanthine significantly improves its effectiveness and shows promise for treating lung fibrosis linked to COVID-19.

Comparison of Viral RNA–Host Protein Interactomes Across Pathogenic RNA Viruses Informs Rapid Antiviral Drug Discovery for SARS-CoV-2

research Comparison of Viral RNA–Host Protein Interactomes Across Pathogenic RNA Viruses Informs Rapid Antiviral Drug Discovery for SARS-CoV-2

100 citations , November 2021 in “Cell Research”

Cepharanthine and Trifluoperazine are effective against SARS-CoV-2.

Cepharanthine: A Review of the Antiviral Potential of a Japanese-Approved Alopecia Drug in COVID-19

research Cepharanthine: A Review of the Antiviral Potential of a Japanese-Approved Alopecia Drug in COVID-19

70 citations , July 2020 in “Pharmacological Reports”

Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.